To evaluate the safety and tolerability of MM-093, as compared to placebo, when administered as a monotherapy once a week for 24 weeks after discontinuing IMT therapy. [clinicaltrials_resource:70f339cf0c3705114c46c90f987159a5]
60 mg, administered subcutaneously, weekly
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
To evaluate the safety and tolerability of MM-093, as compared to placebo, when administered as a monotherapy once a week for 24 weeks after discontinuing IMT therapy. [clinicaltrials_resource:70f339cf0c3705114c46c90f987159a5]
60 mg, administered subcutaneously, weekly
Bio2RDF identifier
70f339cf0c3705114c46c90f987159a5
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:70f339cf0c3705114c46c90f987159a5
measure [clinicaltrials_vocabulary:measure]
To evaluate the safety and tol ...... ter discontinuing IMT therapy.
description
60 mg, administered subcutaneously, weekly
identifier
clinicaltrials_resource:70f339cf0c3705114c46c90f987159a5
title
To evaluate the safety and tol ...... ter discontinuing IMT therapy.
@en
type
label
To evaluate the safety and tol ...... 339cf0c3705114c46c90f987159a5]
@en